Oasmia Pharmaceutical AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more
Oasmia Pharmaceutical AB (OASMY) - Total Assets
Latest total assets as of September 2025: $150.01 Million USD
Based on the latest financial reports, Oasmia Pharmaceutical AB (OASMY) holds total assets worth $150.01 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oasmia Pharmaceutical AB - Total Assets Trend (2004–2024)
This chart illustrates how Oasmia Pharmaceutical AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oasmia Pharmaceutical AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Oasmia Pharmaceutical AB's total assets of $150.01 Million consist of 21.6% current assets and 78.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.78 Million | 14.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Oasmia Pharmaceutical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oasmia Pharmaceutical AB's current assets represent 21.6% of total assets in 2024, an increase from 6.8% in 2004.
- Cash Position: Cash and equivalents constituted 0.5% of total assets in 2024, down from 5.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, a decrease from 92.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 14.9% of total assets.
Oasmia Pharmaceutical AB Competitors by Total Assets
Key competitors of Oasmia Pharmaceutical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Oasmia Pharmaceutical AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oasmia Pharmaceutical AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oasmia Pharmaceutical AB is currently not profitable relative to its asset base.
Oasmia Pharmaceutical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.38 | 2.97 | 1.94 |
| Quick Ratio | 0.38 | 2.97 | 1.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-10.17 Million | $ 30.89 Million | $ 169.56 Million |
Oasmia Pharmaceutical AB - Advanced Valuation Insights
This section examines the relationship between Oasmia Pharmaceutical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -21.7% |
| Total Assets | $172.88 Million |
| Market Capitalization | $151.35K USD |
Valuation Analysis
Below Book Valuation: The market values Oasmia Pharmaceutical AB's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oasmia Pharmaceutical AB's assets decreased by 21.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oasmia Pharmaceutical AB (2004–2024)
The table below shows the annual total assets of Oasmia Pharmaceutical AB from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $172.88 Million | -21.66% |
| 2023-12-31 | $220.67 Million | -37.99% |
| 2022-12-31 | $355.88 Million | -40.12% |
| 2021-12-31 | $594.31 Million | -31.18% |
| 2020-12-31 | $863.54 Million | -14.11% |
| 2019-12-31 | $1.01 Billion | +55.54% |
| 2018-12-31 | $646.38 Million | +13.78% |
| 2017-12-31 | $568.08 Million | +8.91% |
| 2016-12-31 | $521.58 Million | +1.16% |
| 2015-12-31 | $515.58 Million | +0.20% |
| 2014-12-31 | $514.57 Million | +9.86% |
| 2013-12-31 | $468.38 Million | +5.21% |
| 2012-12-31 | $445.18 Million | +27.26% |
| 2011-12-31 | $349.81 Million | +9.21% |
| 2010-12-31 | $320.32 Million | +78.30% |
| 2009-12-31 | $179.65 Million | +85.02% |
| 2008-12-31 | $97.10 Million | +10.75% |
| 2007-12-31 | $87.67 Million | -27.42% |
| 2006-12-31 | $120.79 Million | +89.64% |
| 2005-12-31 | $63.69 Million | +76.63% |
| 2004-12-31 | $36.06 Million | -- |